ARCHIVES

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

Cancer Research Faces A “Strategic Inflection,” NCI Director Says

April 19, 2002

NCAB Committee Close To Definition Of QRA

February 11, 1983

In Brief: Ways & Means Shakeup Means More Liberal Health Insurance Bill; OMB’s Nutty Rational For Cuts

December 20, 1974

NIH Funding Opportunities Listed

March 13, 2009

NCI Plans $175 Million In Program Cuts To Cover Deficit, Fund New Initiatives

November 17, 2006

Fox Retirement Marks End of Era for NCI Construction Program

October 6, 1989